Indeed, the genetic inhibition of these transporters in BCRP/Pgp KO-mice allowed dasatinib to reach GBM inside the brain and to properly inhibit SRC kinase and its downstream pathways, resulting in reduced tumor growth and increased survival of KO mice as compared with the WT [133]. This evidence concerns the gene PGP and neoplasm.